STTR Phase I: An Advanced Antibiotic Screen of Marine Environmental DNA through a Metabolically Engineered E. coli Strain

Earthgenes Pharmaceuticals, Lexington MA

Investigators

Abstract

This Small Business Technology Transfer (STTR) Phase I research project aims to develop a new method for expressing novel antimicrobials from marine microbial DNA in engineered E. coli. Availability of new antibiotics would be of great value to medicine, as more human pathogens are acquiring resistance to mainstay antibiotic therapy. Moreover, a method for expression and isolation of heterologous natural products in E. coli would also open the door to identification of products with other desired activities, such as anti-tumorigenic compounds.